Contribute Try STAT+ Today

In a first-of-its-kind move by a large drug maker, Novartis (NVS) raised approximately $2.1 billion last week by selling bonds that are tied directly to its progress in making medicines accessible in certain low- and middle-income countries.

Specifically, the stated goal is to expand the number of patients who receive its brand-name medicines by at least 200% by 2025, as well as programs that market medicines to combat leprosy, malaria, Chagas, and sickle cell disease by at least 50% over the same period. If the company fails to meet those expanded access goals, however, investors will receive higher interest payments.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Novartis deserves points for innovating in a historically boring space (corporate bond market) but not so much on the social impact on this one. Expanding market access in LIMCs is a growth opportunity for every business. Too much emphasis is placed on the product a company happens to sell, when social impact is really about how it operates its business and where it contributes to communities along the entire value chain.

  • May one observe that while I am sure our scribe has faithfully copied the Novartis numbers in the last line, the idea that each recipient of NVS largess got $30,000 / USD “last year” is ________ [fill in the blank].
    NOTE – I did that calculation by eye, and rounded same.

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy